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Leslie T. Cooper, MD, FACC
Rochester, Minnesota
Peripheral arterial disease (PAD), diagnosed by decreased
ankle-brachial index (ABI), is a major clinical problem,
affecting 8% of people 60 to 69 years old and at least 18% of
people over age 70 (1). A substantial minority of patients
with PAD report intermittent claudication (IC) (2). As the
population ages, IC is an increasingly common cause of
disability, particularly in elderly women (3). Patients with
PAD have about a 30% rate of coronary artery disease (4)
and a 44% to 52% rate of cerebrovascular disease (5). Thus,
PAD is significant, not only because of disability, but also
because patients with PAD have excess risk of myocardial
infarction, stroke, and death.
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The best treatment for PAD is prevention, with risk-
factor modification targeted at smoking cessation and treat-
ment of diabetes, dyslipidemia, and hypertension. Aspirin
or clopidrogel use decreases the risk of cardiovascular events
for patients with PAD. Good foot care is essential because
trauma can result in nonhealing ulceration and amputation.
Once symptoms of IC develop, treatment should then
emphasize a structured walking program. Exercise rehabil-
itation with risk-factor modification improves pain-free
treadmill walking distance up to threefold and absolute
walking distance (AWD) up to fourfold (6).
PATHOPHYSIOLOGY OF “IC”
Development of novel therapeutic agents depends on an
understanding of the complex pathophysiology of IC. Initial
symptoms of exertional limb ischemia relate to a decrease in
blood flow from proximal arterial atherosclerotic stenoses.
At rest, the blood supply meets the tissue needs, but with
exercise, a supply/demand mismatch occurs that presents as
exertional pain that is relieved by rest. The observation that
platelet activation is increased in patients with PAD led to
the hypothesis that circulating platelet aggregates cause
further microcirculatory obstruction in addition to the
impaired flow from large-vessel atherosclerosis (7). The
rationale for the use of epoprostenol (prostacyclin) and its
derivatives in PAD come from their ability to vasodilate and
impair platelet function. However, several studies suggest
that calf blood flow is not the sole or even major determi-
nant of maximal walking distance (8). Other factors, includ-
ing altered carnitine metabolism (9) or atrophy of type II
skeletal muscle nerve fibers, play a role in the symptoms of
chronic IC (10).
CURRENT MEDICAL TREATMENT OF “IC”
The pharmacologic treatment of IC in the U.S. is limited to
pentoxifylline (Trental) and cilostazol (Pletal) (11). Both
drugs have been shown to increase pain-free walking time
and total distance walked, although the data regarding
pentoxifylline conflict. In a recent, randomized comparison
of pentoxifylline and cilostazol, pentoxifylline had no sig-
nificant effect on maximal walking distance or quality of life.
In contract, cilostazol was associated with an improvement
in functional status as assessed by the SF-36 and walking
impairment questionnaire (12). Although cilostazol often
results in modest improvement in IC, its use is contraindi-
cated in patients with heart failure, and a sizable minority
discontinue treatment due to gastrointestinal upset or pal-
pitations. Two additional agents, nafidrofuryl, a serotonin
(5-Hydroxytryptophan) antagonist, and buflomedil, an
alpha-1 and -2 adrenolytic agent, are used outside the U.S.
to a limited degree.
Although there is no evidence that antiplatelet agents
improve walking distance, clopidrogel—or aspirin with or
without dipyridamole—is indicated to reduce the risk of
cardiovascular events. Among the 6,452 patients with PAD
in the CAPRIE study, the risk of myocardial infarction,
ischemic stroke, or vascular death was 3.71% in the
clopidrogel-treated group compared with 4.86% in the
aspirin-treated group, a 3.8% relative risk reduction (p 
0.0028). In a meta-analysis of 11 trials involving over 2,000
patients, the use of antiplatelet agents was associated with a
reduced risk of vascular graft occlusion from 24% to 16%
(13). Peripheral arterial bypass or percutaneous revascular-
ization is often an excellent choice for claudicants with
aortoiliac atherosclerosis who do not respond to an initial
trial of conservative regimen.
THERAPEUTIC RATIONALE FOR
PROSATNOIDS FOR THE TREATMENT OF “IC”
Prostaglandin (PGE1) and prostacyclin (PGI2) analogues
have several biologic actions that suggest a possible thera-
peutic benefit in PAD. During treadmill exercise, platelet
activation, aggregation, and release of mitogens is increased
in PAD patients. In models of atherosclerosis, platelet
granule products cause a proportion of vascular smooth
muscle cells to activate and migrate into atherosclerotic
plaques. These observations suggest that the balance of
arterial vasodilation and constriction would lean toward
constriction in patients with chronic PAD. Beraprost is an
orally active PGI2 analogue that inhibits platelet aggrega-
tion, suppresses smooth muscle proliferation, and promotes
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vasodilation. The convenience of oral administration and
the possibility of three-times daily dosing suggested that
beraprost could be useful in the treatment of chronic IC.
PREVIOUS STUDIES OF PROSTANOIDS
FOR PERIPHERAL VASCULAR DISEASE
In the first randomized trial of epoprostenol (prostacyclin)
for the treatment of rest ischemia, continuous intravenous
(IV) infusion was associated with short-term improvement
in pain (14). Recently, a multicenter trial of alprostadil--
cyclodextrine (administered by 2 h infusion daily for 19
days) also demonstrated short-term improvement in critical
limb ischemia (15). In a pooled analysis, a decrease in major
amputation or death was sustained up to six months after
treatment in patients with critical limb ischemia, suggesting
that short-term or intermittent administration of prosta-
noids was not simply the result of vasodilatation and might
result in sustained clinical efficacy (16).
Enthusiasm for the use of intravenous PGI2 for IC
treatment accelerated after a placebo-controlled trial dem-
onstrated improved walking distance (17). In a study of 80
patients with IC, intravenous AS-103, a PGE1 pro-drug
with extended half-life, demonstrated modest improvement
in maximal and pain-free walking distance (18). The ad-
vantage of AS-103 over prostacyclin is that a bolus injection
can be used rather than continuous IV infusion.
Inconvenient IV dosing of prostaglandin and prostacyclin
led to the development of more stable, orally active ana-
logues. Beraprost sodium, the agent used in the study by
Mohler et al. (19), decreases platelet aggregation in vivo
with a half-life in serum of 30 to 54 min (20). Two
multicenter, randomized, placebo-controlled trials of bera-
prost conducted in Europe demonstrated modest efficacy in
improved pain-free walking distance. The BERCI dose-
ranging study (21) and the BERCI-2 (22) are limited by
relatively small size. The BERCI dose-ranging study en-
rolled 164 in four treatment groups, and the BERCI 2 study
enrolled 422 patients in two treatment groups. The data
from U.S. studies revealed no improvement in walking
distance. The lack of efficacy had been attributed to the
timing of beraprost dosing (with meals). In these studies,
facial flushing, headache, and nausea were the most com-
monly reported side effects.
CONTRIBUTION OF THE PRESENT STUDY
TO THE UNDERSTANDING OF “PAD” TREATMENT
The study by Mohler et al. (19), published in this issue of
the Journal, is the largest well designed study of any
prostanoid for the treatment of IC. Their results were
remarkably consistent. There was no improvement in any of
the pre-defined efficacy end points, including absolute and
pain-free walking distance. The magnitude of increase in
AWD was much lower than had been observed in
BERCI-2. The AWD improved 16.7% and 14.6% in the
treatment and placebo groups, compared with 60.1% and
35.0% in BERCI-2.
Why was the present study negative? Perhaps the study
enrolled a population that differed significantly from those
in the European studies. Ankle-brachial index were lower in
the present study than in BERCI-2. However, this is not
likely to be the case, because the subjects in BERCI-2 with
the lower ABI had the greatest improvement in AWD.
Perhaps the lack of efficacy was due to the greater rate of
co-morbidities including diabetes, dyslipidemia, and hyper-
tension in the present study. Possibly the dosing regimen
may have left too great a window without significant drug
levels to cause a lasting biologic effect in the vasculature.
The half-life of beraprost is 1 h. Even with 100%
compliance, there would be 3 h of drug exposure per day.
The more likely explanation for their negative efficacy
results is that the underlying hypothesis that platelet micro-
aggregates contribute to claudication is wrong. The size of
microaggregates would probably be too small to occlude
even a tightly stenosed iliac or superficial femoral artery.
The vasodilatory effects of beraprost observed in animal
models and volunteers would probably not add much flow in
maximally vasodilated distal vascular beds.
A secondary and intriguing finding in the present study
was a decrease in cardiovascular events in the beraprost
treated patients. This is consistent with many observations
of other platelet inhibitors and supports the established
hypothesis that platelet thrombosis is important in most
coronary events.
THE FUTURE OF MEDICAL
THERAPY FOR CLAUDICATION
The study by Mohler et al. (19) was well designed and adds
to our knowledge of IC treatment. Beraprost lacks efficacy
and probably has too many side effects to be an effective
treatment for IC in clinical practice. We know from
previous clinical trials that IV prostanoid formulations may
mildly increase walking distance, but the inconvenience and
expense of IV administration of these agents is dispropor-
tionate to the benefits. Therefore, it is unlikely that prosta-
noids will be used clinically for IC caused by large-vessel
atherosclerosis.
It is important to note that the present study did not
evaluate limb ischemia resulting from other causes such as
thromboangiitis obliterans (Buerger’s disease) or atheroem-
bolism. In these disorders, the level of arterial occlusion is in
the smaller vessels in which platelet thrombi and microvas-
cular occlusion may have a more substantial pathophysio-
logic role. Furthermore, the present study does not apply to
critical limb ischemia or ischemic wound healing. Patients
with more severe or diffuse atherosclerosis who are not
candidates for revascularization may benefit from prostanoid
therapy.
Future research is likely to focus on agents that favorably
alter the metabolic state of skeletal muscle such as
1688 Cooper JACC Vol. 41, No. 10, 2003
Editorial Comment May 21, 2003:1687–9
L-arginine and propyl-L-carnitine. In the next two years, the
results of major trials of statins, antiplatelet agents, recom-
binant growth factors, and immune modulators for IC will
be available. The publication of the Mohler et al. (19) study
in a high-profile cardiovascular journal such as the Journal of
the American College of Cardiology is particularly warranted at
this time because it emphasizes the importance of IC as a
marker of cardiovascular morbidity and the need to establish
interventions that improve clinically meaningful end points.
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